AngioDynamics, Inc. provided sales guidance for the Fiscal Year 2024. For the year, the company expects net sales to be in the range of $270 million to $275 million which reflects the recent divestiture of the PICC and Midline businesses and discontinuance of the RadioFrequency ablation and Syntrax businesses, which accounted for approximately $50 million of the prior revenue guidance of $320 to $325 million. The Company expects gross margin to be approximately 52.0% to 54.0%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.05 USD | -1.14% | -3.51% | -22.83% |
May. 06 | AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV) | CI |
Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.83% | 242M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.84% | 40.7B | |
+24.51% | 32.25B | |
+3.43% | 26.53B | |
+15.25% | 25.02B |
- Stock Market
- Equities
- ANGO Stock
- News AngioDynamics, Inc.
- AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024